A purple and pink letter v on a white background.
August 16, 2024

American Society of Plastic Surgeons: Can robotic artificial intelligence improve hair restoration?

Adult men and women will naturally encounter changes in hair thickness and hair density with age. This process of hair loss is known as adult alopecia and varies by individual. Researchers have definitively linked most cases of adult-onset alopecia to normal aging, genetics and overall health.

For those patients experiencing alopecia, clinicians usually recommend a medical evaluation by a board-certified plastic surgeon who is an ASPS member to assess the causes of hair loss. If your physician finds no disease-related conditions affecting hair growth, he or she may recommend a procedure known as a hair restoration.


During hair restoration, surgeons harvest individual hair follicles from one area of the scalp and transplant them to other areas that are experiencing hair loss. It is very common to remove healthy hair follicles from the back of the head and transplant these hair follicles to the hairline and crown through a process known as follicular unit extraction (FUE).



Advancements in robotic technology and artificial intelligence have further improved the results of FUE hair transplantation by more accurately harvesting and implanting hair follicles during a hair transplant. These revolutionary processes allow experts to optimize results and improve efficiency.


What is robotic hair restoration?

Robotic hair restoration was developed in Silicon Valley and uses artificial intelligence to enable a laser-guided robot to extract individual hair follicles and then transplant those hair follicles to physician-guided hairline designs.

In the past, the extraction of hair was performed by removing a strip of the scalp and moving it to the balding area in a procedure known as follicular unit transplantation (FUT), or manually extracting individual hair follicles using hand-held tools and moving them to the balding area of the scalp.


What is the robotic hair restoration system called?

The ARTAS® system was developed as a collaboration of physicians, robotic engineers and software developers to facilitate and optimize the harvesting and implantation of hair follicles in the scalp. There are over 190 patents related to the design and manufacturing of the equipment, which is used by advanced hair restoration experts worldwide.


How does artificial intelligence play a role in robotic hair restoration?

Artificial intelligence allows the robotic device to assess the position, angle, orientation and density of hair follicles from the donor and recipient areas. In doing so, it allows stereoscopic mapping of the scalp so that the hair follicles are best preserved during the harvesting of hair and the transplantation of the follicles.

Both a physician and technician work alongside the device to optimize functionality and to implement the accuracy and reproducibility of results. The goal of the artificial intelligence system is to improve the precision of hair transplantation techniques.

Robotic hair transplantation uses technology to facilitate the process of removing donor hair and transplanting it back into the scalp. It is not necessarily a faster or quicker type of procedure, but one that minimizes variability by standardizing how the implants are removed, sorted and implanted back into the hairline.


Is everyone with hair loss a candidate for hair transplantation?

If you are experiencing hair loss as an adult, there are many factors that influence the rate and severity of the problem. Your medical history, family history of hair loss and your age can affect how much hair you have as an adult.

A hair transplant surgeon will determine your treatment options based on whether you have enough donor hair to transplant or if it is a better idea to undergo less invasive treatment for hair stimulation.


Can the robot do the hair transplantation alone?

Robotic hair transplantation is an evolving technology that is being utilized in modern medicine. The company that produces the first and only robotic AI machine, known as ARTAS®, continues to develop the technology to further optimize results.

Currently, the robotic technology works alongside a physician to remove donor hair and re-implant it in the hairline. The physician will continue to make decisions on the candidacy of a patient, the amount of hair to be removed and transplanted plus the distribution of the hair along the hairline and scalp.

As these technologies evolve, we will continue to see growth in hair transplantation techniques as the methods move from purely surgical options to less invasive approaches that utilize technology to plan and implement the procedure. Robotic hair transplantation is currently being used in practice and will continue to be a valuable addition to the arsenal of options available for hair restoration.


The views expressed in this blog are those of the author and do not necessarily reflect the opinions of the American Society of Plastic Surgeons.


September 9, 2026
TORONTO, September 9 th , 2026 (GLOBE NEWSWIRE) – Venus Concept Inc. (“Venus Concept” or the “Company”), a global medical aesthetic technology leader, today announced the appointment of Brad Oliver as Chief Executive Officer, effective as of September 7, 2026. He succeeds Rajiv De Silva, who will assume the role of Special Advisor to support a seamless leadership transition. The Board believes that Brad’s commercial leadership experience, strategic vision, and industry expertise position the Company well for its next phase of growth and value creation. Brad brings more than 20 years of leadership experience in the aesthetic industry, most recently as President & General Manager – Americas at Lumenis, and has a proven track record of driving growth globally, operational excellence, and innovation. "I am honored to be appointed Chief Executive Officer of Venus Concept and grateful for the confidence the Board has placed in me,” said Mr. Oliver. “The Company has established a strong foundation under Rajiv's leadership, and I look forward to working closely with him during the transition. Together with our employees, customers, and partners, we will remain focused on disciplined commercial execution, product innovation, profitable growth, and creating long-term value for our customers, employees, and shareholders.” “It has been a pleasure to lead Venus through a transformational time in the organization’s journey,” said Mr. De Silva. “I am grateful for the opportunity to work together with the leadership team, the Board and our partners to grow the business. We have transformed the commercial, operational and financial capabilities of the organization and built a strong foundation for the future. I remain highly confident in the Company’s strategy, pipeline and long-term growth opportunities. I look forward to supporting a smooth transition and watching Venus continue its transformation under Brad’s new leadership.” The Board expresses its gratitude to Rajiv for his leadership and ongoing commitment to the Company. As Special Advisor, Rajiv will work closely with Brad during the transition period to ensure continuity across strategic, operational, and customer-facing initiatives. “On behalf of the Board, I would like to thank Rajiv for his leadership and contributions to the Company and for his support during this transition to ensure a seamless handoff of leadership responsibilities,” said Avinash Amin, M.D., Managing Partner of Madryn Asset Management and Chairman of the Board. “The Board looks forward to Brad’s new leadership of the organization and is confident that his expertise will accelerate commercial efforts globally and the execution of its strategic priorities as the company progresses towards continuing to establish a leadership position in the Medical Device Aesthetics industry.” The leadership transition is not expected to impact the Company’s strategic priorities, customer relationships, employee commitments, or ongoing business operations. Venus Concept remains focused on delivering innovative solutions to its customers, expanding market opportunities, and driving sustainable long-term growth. About Venus Concept Venus Concept is an innovative global medical aesthetic technology leader with a broad product portfolio of minimally invasive and non-invasive medical aesthetic and hair restoration technologies and reaches over 60 countries and 9 direct markets. Venus Concept's product portfolio consists of aesthetic device platforms, including Venus NOVA, Venus Versa, Venus Versa PRO, Venus Bliss, Venus Bliss MAX, Venus Viva, Venus Viva MD, Venus Legacy, Venus Velocity, Venus Epileve and AI.ME. Venus Concept's hair restoration systems include NeoGraft ® and the ARTAS iX ® Robotic Hair Restoration system. Venus Concept is backed by Madryn Asset Management, a leading healthcare investment firm that provides capital to innovative growth-stage healthcare companies offering unique and transformative products and technologies. View Full Article Investor Relations Contact : Damian Yeung, CPA investorrelations@venus.ai
By Yoni Nowmalki July 28, 2026
TORONTO, July 28, 2026 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”), a global medical aesthetic technology leader, today announced it has entered into an exclusive distribution agreement with HIRONIC Co. Ltd. (“HIRONIC”), a KOSDAQ listed South Korean company specializing in medical aesthetic devices, pursuant to which the Company acquires the exclusive right to distribute HIRONIC’s Doublo 2.0 device in the United States and Canada. The “New Doublo 2.0” is a synergistic, multi-energy-based medical device platform for the face and body, equipped with two separate handpieces that enables clinics to offer customer Cold Plasma and RF microneedling treatments. The device has received 510(k) certification from the U.S. Food and Drug Administration, and the Company intends to make it available to customers in the United States during 2H 2026. Venus Concept will support future regulatory approval efforts in Canada for the device and any additional handpiece technologies for both regions. “HIRONIC is a global leader in developing innovative medical aesthetic technologies and we are excited for the new partnership, starting with the Doublo x Venus Signature Edition,” said Rajiv De Silva, Chief Executive Officer of Venus Concept. “With this device, we look forward to offering our customers an innovative, exclusive Cold Plasma and RF Microneedling platform. By combining these complementary technologies, the platform delivers synergistic effects from the epidermis to the dermis, enabling comprehensive skin rejuvenation by addressing multiple skin concerns and enhancing overall skin revitalization. The Doublo also complements our existing portfolio by enhancing the range of treatment modalities for a customizable treatment plan to address each patient’s skin needs. We aim to expand our partnership in the future to bring to our customers additional new and novel technologies from HIRONIC, once regulatory approvals have been obtained.” About Venus Concept Venus Concept is an innovative global medical aesthetic technology leader with a broad product portfolio of minimally invasive and non-invasive medical aesthetic and hair restoration technologies and reaches over 60 countries and 9 direct markets. Venus Concept's product portfolio consists of aesthetic device platforms, including Venus NOVA, Venus Versa, Venus Versa PRO, Venus Bliss, Venus Bliss MAX, Venus Viva, Venus Viva MD, Venus Legacy, Venus Velocity, Venus Epileve and AI.ME. Venus Concept's hair restoration systems include NeoGraft® and the ARTAS iX® Robotic Hair Restoration system. Venus Concept is backed by Madryn Asset Management, a leading healthcare investment firm that provides capital to innovative growth-stage healthcare companies offering unique and transformative products and technologies. Investor Relations Contact: Damian Yeung, CPA investorrelations@venus.ai View Full Article
May 22, 2026
Skin Cancer Awareness Month highlights prevention and early detection. Learn how dermatologists support care with advanced tools and treatments.